GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Shares Outstanding (EOP)

ArriVent BioPharma (ArriVent BioPharma) Shares Outstanding (EOP) : 33.49 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ArriVent BioPharma's shares outstanding for the quarter that ended in Mar. 2024 was 33.49 Mil.

ArriVent BioPharma's quarterly shares outstanding increased from Dec. 2023 (31.96 Mil) to Mar. 2024 (33.49 Mil). It means ArriVent BioPharma issued new shares from Dec. 2023 to Mar. 2024 .

ArriVent BioPharma's annual shares outstanding declined from Dec. 2022 (31.96 Mil) to Dec. 2023 (31.96 Mil). It means ArriVent BioPharma bought back shares from Dec. 2022 to Dec. 2023 .


ArriVent BioPharma Shares Outstanding (EOP) Historical Data

The historical data trend for ArriVent BioPharma's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Shares Outstanding (EOP) Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23
Shares Outstanding (EOP)
- 31.96 31.96

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only 31.96 31.96 31.96 31.96 33.49

Competitive Comparison of ArriVent BioPharma's Shares Outstanding (EOP)

For the Biotechnology subindustry, ArriVent BioPharma's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Shares Outstanding (EOP) falls into.



ArriVent BioPharma Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


ArriVent BioPharma  (NAS:AVBP) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


ArriVent BioPharma Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma (ArriVent BioPharma) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus